In Valeant’s Bid for Allergan, an Opaque Business Model Is Revealed by JESSE EISINGER

By JESSE EISINGER

Nobody really knows if Valeant Pharmaceuticals is doing anything that makes money, or is just engaged in prestidigitation that never gets anywhere, writes Jesse Eisinger in The Trade.

Published: June 4, 2014 at 4:00AM

from NYT Business Day http://ift.tt/1oaC1dU

from WordPress http://ift.tt/1kLGs96

via Hadi Aboukhater